Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Melanoma × Methods × Clear all

Phase

Phase NA 4 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 2 Motor Activity 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Prostate Adenocarcinoma 1 Pancreatic Cancer Liver Metastases 1 Neoplasms 1 Melanoma 1 Colorectal Neoplasms 1 Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8 1

Interventions

Ipilimumab 90 Nivolumab 86 pembrolizumab 79 aldesleukin 62 Cyclophosphamide 40 Interleukin-2 38 trametinib 28 dabrafenib 27 fludarabine phosphate 26 Dacarbazine 26 Temozolomide 25 Vemurafenib 24 incomplete Freund's adjuvant 23 Bevacizumab 23 sargramostim 21 fludarabine 21 Radiosurgery 19 binimetinib 17 encorafenib 16 cobimetinib 15 Paclitaxel 15 Carboplatin 13 atezolizumab 12 Radiotherapy 12 Sorafenib 11 Biopsy 11 talimogene laherparepvec 10 montanide ISA 51 10 MART-1 Antigen 10 CTLA-4 Antigen 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05388851 2025-06-22

Education for Prevention of Melanoma in Hispanic Populations

Mayo Clinic

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡